GNBT News
Press Release Source: Generex Biotechnology
Generex Biotechnology Receives Additional Patent in Mexico
Monday April 24, 7:30 am ET
Company Expands Drug Delivery Platform Patent Portfolio
TORONTO--(MARKET WIRE)--Apr 24, 2006 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News) announced today that it has been granted a patent by the Mexico National Registry of Patents titled "Aerosol Pharmaceutical Formulation for Pulmonary and Nasal Delivery."
The patent, an extant United States Patent registered by the Company, relates to an improved delivery system for the administration of large-molecule pharmaceuticals which may be administered by means of an aerosol into the mouth for buccal, nasal or pulmonary application.
"We are happy to further enhance the Company's existing drug delivery platform patent portfolio in the region and which emphasizes the broad application of our platform technology," said Rose Perri, the Company's Chief Operating Officer. "We look forward to developing and improving existing aerosol pharmaceutical formulations using the Company's RapidMist(TM) system."
The Company currently holds an aggregate of 72 patents worldwide (19 of which are United States patents) and has an aggregate of 58 patent applications pending in various jurisdictions.
About Generex
Generex is engaged in the research and development of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist(TM) device. The Company's flagship product, oral insulin (Oral-lyn(TM)), which has been approved for commercial sale in Ecuador for the treatment of patients with Type-1 and Type-2 diabetes, is in various stages of clinical trials around the world.
For more information, visit the Generex website at www.generex.com.
Safe Harbor Statement: This release and oral statements made from time to time by Generex representatives concerning the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects" or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts. Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not. Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement. No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements. Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials. Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials. Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act
AI
